Boehringer Ingelheim

Pharmaceutical company Boehringer Ingelheim GmbH (established in 1885) is among the world’s top 20 pharmaceutical companies. Around 50 000 employees are creating long-term value through innovation in three key areas: Human pharmaceuticals, biopharmaceuticals and animal health. Boehringer Ingelheim is devoted to serving humankind by conducting research to treat diseases and develop breakthrough therapies. The company was recently rated among the top 100 innovative companies of all industrial sectors worldwide. The company’s new research strategy aims at treating diseases with high-unmet medical needs. To this end, the company announced the funding of their research program with 11.5 billion Euros; More than 8000 Boehringer Ingelheim employees work in R&D alone and focus on developing innovative therapies based on own resources, through partnerships, and strategic research alliances.

In Greece, the Boehringer Ingelheim affiliate is founded in 1966. Today it is considered a market leader among the country’s top 10 pharmaceutical companies. Boehringer Ingelheim direct contribution to the Greek GDP in 2018 amounted to €310 milion. This equals 8% of the Greek pharmaceutical industry’s Gross Value Added (GVA). Including spillover effects, the company contributed more than €308 million in GVA. The firm’s human resources comprise leading scientists and sector professionals with the required skills, education and experience to implement its objectives and promote Boehringer Ingelheim vision “Value through Innovation”. Beyond its 545 employees in Greece (2020) , Boehringer Ingelheim triggered about 5,800 indirect and 1,600 induced jobs in Greek supply chains, thereby supporting a total of almost 7,700 jobs in the Greek labor market.

Boehringer Ingelheim Ellas as an innovation leader participates actively in the parent company’s international clinical research program. During the last 10 years  has conducted 45 international multicenter studies in Greece that enrolled over 2,700 patients, with more than 20 million euros invested to this end. Boehringer Ingelheim Ellas has awarded several times for its innovative medicines in the most significant therapeutic areas of respiratory, cardiovascular, pain management, and recently diabetes and oncology. The Prix Galien prizes of 2017 and 2019 in the field of rare diseases was among the various awards Boehringer Ingelheim Ellas received for its innovation

The company owns its production facility in Koropi, Attica, established in 1975. Today, it is the only multinational pharmaceutical company that maintains its industrial production facility in Greece, supplying not only the Greek market but also the markets of more than 68 countries. Its export activity is of particular importance not only to the firm itself, but also to the country’s economy, as it accounts for about 2,2% of total Greek exports, establishing Boehringer Ingelheim Ellas as a production & exports leader.

Its parent company recently entrusted Boehringer Ingelheim Ellas with the production of innovative antidiabetic drugs at the Greek plant, aimed at covering a large part of its international production, which is a ‘first’ in the company’s history. Such actions and investments in production and export activity by Boehringer Ingelheim Ellas – with exports being its strong asset, stand proof of the confidence shown by the German multinational and its intention not only to upgrade its Greek subsidiary, but also to support and boost Greek exports. For this grate investment, Boehringer Ingelheim Ellas received the Prix Galien 2019 honorable distinction.

Boehringer Ingelheim Ellas’ initiatives for Greece’s economy are summarized in the triptych: “We Invest, We Grow, We Support.”